FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096470130> ?p ?o ?g. }

• W2096470130 endingPage "30" @default.
• W2096470130 startingPage "22" @default.
• W2096470130 abstract "Background: The long-term outcome for patients with aggressive non-Hodgkin's lymphoma (NHL) is poor. Consequently, the European Organization for Research and Treatment of Cancer Lymphoma Group designed a prospective randomized trial to investigate whether high-dose chemotherapy plus autologous bone marrow transplantation (ABMT) after standard combination chemotherapy improves long-term survival. Methods: Patients aged 15–65 years with aggressive NHL received three cycles of CHVmP/BV polychemotherapy (i.e., a combination of cyclophosphamide, doxorubicin, teniposide, and prednisone, with bleomycin and vincristine added at mid-cycle). After these three cycles, patients with a complete or partial remission and at that time no lymphoma involvement in the bone marrow were randomly assigned to the ABMT arm (a further three cycles of CHVmP/BV followed by BEAC [i.e., a combination of carmustine, etoposide, cytarabine, and cyclophosphamide] chemotherapy and ABMT) or to the control arm (five more cycles of CHVmP/BV). All statistical tests are two-sided. Results: From December 1990 through October 1998, 311 patients (median age = 44 years) were registered and received the first three cycles of CHVmP/BV, and 194 patients were randomly assigned to the treatment arms. Approximately 70% (140 patients) of these patients were of low or low–intermediate International Prognostic Index (IPI) risk. After a median follow-up of 53 months, an intention-to-treat analysis showed a time to disease progression and overall survival at 5 years of 61% (95% confidence interval [CI] = 51% to 72%) and 68% (95% CI = 57% to 79%), respectively, for the ABMT arm and 56% (95% CI = 45% to 67%) and 77% (95% CI = 67% to 86%), respectively, for the control arm. Differences between arms were not statistically significant. A subset analysis on IPI risk groups, although too small for reliable statistical analysis, yielded similar results. Conclusions: Standard combination therapies remain the best choice for most patients with aggressive NHL. We recommend that patients with IPI low or low–intermediate risk not be subjected to high-dose chemotherapy and ABMT as a first-line therapy." @default.
• W2096470130 created "2016-06-24" @default.
• W2096470130 creator A5009072957 @default.
• W2096470130 creator A5014610990 @default.
• W2096470130 creator A5022420944 @default.
• W2096470130 creator A5034356923 @default.
• W2096470130 creator A5042799541 @default.
• W2096470130 creator A5045745778 @default.
• W2096470130 creator A5053031492 @default.
• W2096470130 creator A5064987276 @default.
• W2096470130 creator A5070508738 @default.
• W2096470130 creator A5081216142 @default.
• W2096470130 creator A5085711290 @default.
• W2096470130 creator A5090023600 @default.
• W2096470130 date "2001-01-03" @default.
• W2096470130 modified "2023-09-26" @default.
• W2096470130 title "Standard Chemotherapy With or Without High-Dose Chemotherapy for Aggressive Non-Hodgkin's Lymphoma: Randomized Phase III EORTC Study" @default.
• W2096470130 cites W1544519462 @default.
• W2096470130 cites W1598952549 @default.
• W2096470130 cites W1819949687 @default.
• W2096470130 cites W1830589476 @default.
• W2096470130 cites W1877303819 @default.
• W2096470130 cites W1937538988 @default.
• W2096470130 cites W1954969898 @default.
• W2096470130 cites W1973498337 @default.
• W2096470130 cites W2000366267 @default.
• W2096470130 cites W2060499368 @default.
• W2096470130 cites W2107202569 @default.
• W2096470130 cites W2107639967 @default.
• W2096470130 cites W2225927535 @default.
• W2096470130 cites W2243140240 @default.
• W2096470130 cites W2255094305 @default.
• W2096470130 cites W2259377666 @default.
• W2096470130 cites W2313423582 @default.
• W2096470130 cites W2318772898 @default.
• W2096470130 cites W2334624221 @default.
• W2096470130 cites W2338377114 @default.
• W2096470130 cites W2339293928 @default.
• W2096470130 cites W2343527457 @default.
• W2096470130 cites W3024436806 @default.
• W2096470130 cites W4205736005 @default.
• W2096470130 cites W4235885205 @default.
• W2096470130 cites W4240026283 @default.
• W2096470130 cites W4241762497 @default.
• W2096470130 cites W4252168887 @default.
• W2096470130 doi "https://doi.org/10.1093/jnci/93.1.22" @default.
• W2096470130 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11136838" @default.
• W2096470130 hasPublicationYear "2001" @default.
• W2096470130 type Work @default.
• W2096470130 sameAs 2096470130 @default.
• W2096470130 citedByCount "137" @default.
• W2096470130 countsByYear W20964701302012 @default.
• W2096470130 countsByYear W20964701302013 @default.
• W2096470130 countsByYear W20964701302014 @default.
• W2096470130 countsByYear W20964701302015 @default.
• W2096470130 countsByYear W20964701302016 @default.
• W2096470130 countsByYear W20964701302022 @default.
• W2096470130 crossrefType "journal-article" @default.
• W2096470130 hasAuthorship W2096470130A5009072957 @default.
• W2096470130 hasAuthorship W2096470130A5014610990 @default.
• W2096470130 hasAuthorship W2096470130A5022420944 @default.
• W2096470130 hasAuthorship W2096470130A5034356923 @default.
• W2096470130 hasAuthorship W2096470130A5042799541 @default.
• W2096470130 hasAuthorship W2096470130A5045745778 @default.
• W2096470130 hasAuthorship W2096470130A5053031492 @default.
• W2096470130 hasAuthorship W2096470130A5064987276 @default.
• W2096470130 hasAuthorship W2096470130A5070508738 @default.
• W2096470130 hasAuthorship W2096470130A5081216142 @default.
• W2096470130 hasAuthorship W2096470130A5085711290 @default.
• W2096470130 hasAuthorship W2096470130A5090023600 @default.
• W2096470130 hasBestOaLocation W20964701301 @default.
• W2096470130 hasConcept C126322002 @default.
• W2096470130 hasConcept C141071460 @default.
• W2096470130 hasConcept C143998085 @default.
• W2096470130 hasConcept C2776581026 @default.
• W2096470130 hasConcept C2776694085 @default.
• W2096470130 hasConcept C2776755627 @default.
• W2096470130 hasConcept C2778041864 @default.
• W2096470130 hasConcept C2778119113 @default.
• W2096470130 hasConcept C2778336483 @default.
• W2096470130 hasConcept C2778476033 @default.
• W2096470130 hasConcept C2778476748 @default.
• W2096470130 hasConcept C2779338263 @default.
• W2096470130 hasConcept C2779429289 @default.
• W2096470130 hasConcept C2780039790 @default.
• W2096470130 hasConcept C2780147359 @default.
• W2096470130 hasConcept C71924100 @default.
• W2096470130 hasConceptScore W2096470130C126322002 @default.
• W2096470130 hasConceptScore W2096470130C141071460 @default.
• W2096470130 hasConceptScore W2096470130C143998085 @default.
• W2096470130 hasConceptScore W2096470130C2776581026 @default.
• W2096470130 hasConceptScore W2096470130C2776694085 @default.
• W2096470130 hasConceptScore W2096470130C2776755627 @default.
• W2096470130 hasConceptScore W2096470130C2778041864 @default.
• W2096470130 hasConceptScore W2096470130C2778119113 @default.
• W2096470130 hasConceptScore W2096470130C2778336483 @default.
• W2096470130 hasConceptScore W2096470130C2778476033 @default.
• W2096470130 hasConceptScore W2096470130C2778476748 @default.

• next